The DOI matches its Crossref record.
Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy
Abstract
Proteinuria is a risk factor for progression of chronic renal failure. A model of proteinuria-associated tubulointerstitial injury was developed and was used to examine the therapeutic effect of rapamycin. Two studies were performed. In study A, proteinuric rats were given sheep anti-Fx1A to induce experimental membranous nephropathy; control rats received normal sheep serum. Four weeks later, groups were subdivided and underwent laparotomy alone (two kidneys), nephrectomy alone (one kidney), or nephrectomy with polectomy (0.6 kidney). Renal function and morphology were evaluated 4 wk later. Whereas control rats never developed proteinuria, anti-Fx1A induced severe proteinuria. Proteinuria was unaffected by renal mass reduction. Proteinuric rats developed tubulointerstitial disease that was most severe in rats with 0.6 kidneys. Renal function (GFR) was reduced by loss of renal mass and was reduced further in proteinuric rats with 0.6 kidneys. In study B, the effect of rapamycin on the expression of candidate proinflammatory and profibrotic genes and the progression of proteinuria-associated renal disease were examined. All rats received an injection of anti-Fx1A and were nephrectomized and then divided into groups to receive rapamycin or vehicle. Gene expression, renal morphology, and GFR were evaluated after 4, 8, and 12 wk. Rapamycin reduced expression of the proinflammatory and profibrotic genes (monocyte chemotactic protein-1, vascular endothelial growth factor, PDGF, TGF-beta(1), and type 1 collagen). Tubulointerstitial inflammation and progression of interstitial fibrosis that were present in vehicle-treated rats were ameliorated by rapamycin. Rapamycin also completely inhibited compensatory renal hypertrophy. In summary, rapamycin ameliorates the tubulointerstitial disease associated with chronic proteinuria and loss of renal mass.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
How Does Proteinuria Cause Progressive Renal Damage?
Abbate, M., Zoja, C., & Remuzzi, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006040377 · Cited by 779
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Lieberthal, W., & Levine, J. S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111186 · Cited by 280
Self-citationActivation of Sirt1 by Resveratrol Inhibits TNF-α Induced Inflammation in Fibroblasts
Zhu, X., Liu, Q., Wang, M., Liang, M., Yang, X., Xu, X., Zou, H., & Qiu, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027081 · Cited by 255
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Sofroniadou, S., & Goldsmith, D. (2011) · Drug Safety · doi:10.2165/11585040-000000000-00000 · Cited by 60
Metadata
- Authors
- Bonegio, R. G. B., Fuhro, R., Wang, Z., Valeri, C. R., Andry, C., Salant, D. J., & Lieberthal, W.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-07
- Volume
- 16
- Issue
- 7
- Pages
- 2063-2072
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2159110261
- Cited by
- 162
- References
- 0
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2004030180
- The paper
- Bonegio, R. G. B., Fuhro, R., Wang, Z., Valeri, C. R., Andry, C., Salant, D. J., & Lieberthal, W. (2005). Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2004030180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.